Welcome to our dedicated page for Icecure Medical Ltd. news (Ticker: ICCM), a resource for investors and traders seeking the latest updates and insights on Icecure Medical Ltd. stock.
IceCure Medical Ltd. (Nasdaq: ICCM) is a commercial-stage medical device company that develops liquid-nitrogen-based cryoablation systems for minimally invasive destruction of benign and cancerous tumors. News about IceCure often centers on its flagship ProSense® Cryoablation System and its role as an option to surgical tumor removal, particularly in breast cancer and other oncology indications.
Investors and clinicians following ICCM news can expect updates on regulatory milestones, commercial expansion, and clinical data. Recent company communications highlight U.S. Food and Drug Administration (FDA) marketing authorization for ProSense® for the local treatment of low-risk breast cancer with adjuvant endocrine therapy in women aged 70 and above, including those not suitable for surgery. News items also cover regulatory approvals in markets such as Switzerland and Israel, as well as patent developments for next-generation systems like XSense™ and cryogen flow control technologies.
IceCure’s news flow frequently includes coverage of independent clinical studies and conference presentations. ProSense® has been featured in abstracts and talks at major meetings such as the Radiological Society of North America (RSNA) Annual Meeting, the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) Annual Meeting, and the European Society of Breast Imaging (EUSOBI) Congress. These reports describe clinical experience in breast cancer, lung cancer, musculoskeletal tumors, kidney lesions, and abdominal wall endometriosis.
Company updates may also address financial and operational results, commercial traction in regions including North America and Europe, and interactions with Nasdaq listing requirements. For users tracking ICCM, this news page provides a centralized view of press releases, clinical milestones, regulatory developments, and commercialization updates related to IceCure’s cryoablation platforms.
IceCure Medical (NASDAQ:ICCM) showcased its ProSense® cryoablation technology at the CIRSE 2025 Annual Meeting in Barcelona, featuring 4 independent clinical studies demonstrating positive results. The presentations included 3 studies on breast cancer and 1 on endometriosis, highlighting ProSense's effectiveness as a minimally-invasive tumor treatment alternative.
Key findings included successful outcomes in elderly breast cancer patients, with Institut Curie's study showing safety and efficacy in patients aged 75-94 years. Another study demonstrated significant tumor size reduction when combining cryoablation with hormonal therapy. The endometriosis study revealed remarkable pain reduction from a mean score of 8 to 1, with 95% success rate in MRI-confirmed cases.
The conference featured 3 hands-on training sessions and presentations from 5 Key Opinion Leaders, underlining growing interest from interventional radiologists in breast cancer care.
IceCure Medical (NASDAQ: ICCM) has received a Notice of Allowance from the U.S. Patent and Trademark Office for its next-generation XSense™ cryoprobe technology. The innovation enhances the company's liquid-nitrogen-based cryoablation platform, which is used for tumor destruction through freezing as an alternative to surgical removal.
The patented technology features a novel extraction method incorporating a heater, temperature sensor, and controlled gas pulses in the cryoprobe's tip. This advancement enables precise temperature management during probe extraction, reducing tissue trauma risk. The XSense™ System with Cryoprobes has already secured regulatory approval in both the U.S. and Israel.
IceCure Medical (NASDAQ: ICCM) has received regulatory approval from Israel's Ministry of Health for its next-generation XSense™ cryoablation system. The system, which uses liquid-nitrogen based technology to destroy tumors by freezing, has been approved for multiple indications including breast cancer, gynecology, oncology, and general surgery.
The XSense™ System and CryoProbes had previously received FDA clearance in mid-2024 for all indications currently approved for the company's ProSense® system. This minimally invasive treatment option aims to reduce cancer care costs, accelerate patient recovery, and provide an alternative to surgical tumor removal.
IceCure Medical (NASDAQ: ICCM) announced two significant publications from the independent THERMAC Trial evaluating its ProSense® cryoablation system in breast cancer treatment. The trial, conducted in the Netherlands, compared different thermal ablation methods for early-stage breast cancer.
The first study, published in the European Journal of Surgical Oncology, revealed that 95% of patients were satisfied with thermal ablation, with 91% preferring it over surgery. The second publication in Radiology demonstrated that ProSense® achieved the highest complete ablation rate among alternatives, with no complications.
Key findings showed that 94% of thermal ablation cases were rated good or excellent compared to 80% for surgery. ProSense® required no oncoplastic surgery, while other methods needed additional interventions. The successful phase II results led investigators to select cryoablation as the preferred technique for a future phase III trial comparing it with surgery.
IceCure Medical (NASDAQ: ICCM) reported promising results from an independent study evaluating its ProSense® cryoablation system for treating abdominal wall endometriosis (AWE). The study, conducted at Nîmes University Hospital in France, demonstrated significant pain reduction in patients, with median pain scores dropping from 8/10 to 0/10 at 3-month follow-up.
The study included 14 patients with 23 AWE lesions treated between September 2022 and April 2025. Key outcomes showed complete ablation zone coverage, median procedural time of 93 minutes, and no complications. Only 14% of patients required retreatment. ProSense® is FDA-cleared and EU-approved for gynecological indications, targeting a market of approximately 190 million women globally affected by endometriosis.
IceCure Medical (NASDAQ: ICCM) reported financial results for H1 2025, highlighting progress toward FDA marketing authorization for ProSense® in treating early-stage breast cancer in women aged 70+. The company submitted a Post-Market Study plan to FDA, with approval expected by year-end 2025.
Financial highlights include revenue of $1.25M (down from $1.75M in H1 2024), and a successful $10M over-subscribed rights offering. The company reported a net loss of $6.95M ($0.12 per share) and held cash and equivalents of $5.38M as of June 30, 2025.
Clinical developments include strong data from independent studies, with a Japanese study showing 99% recurrence-free rate in over 600 women. The company expects several upcoming milestones, including Terumo's regulatory filing in Japan and XSense™ system approval in Israel.
IceCure Medical (NASDAQ: ICCM), a developer of minimally-invasive cryoablation technology for tumor treatment, will release its financial and operational results for H1 2025 before market open on August 13, 2025.
The company will host a conference call and webcast at 11:00 AM EDT on the same day to discuss the results and corporate developments. Investors can access the call via US toll-free number (1-888-407-2553) or international number (+972-3-918-0696), with a live webcast available through the company's website.
IceCure Medical (NASDAQ: ICCM), a developer of minimally-invasive cryoablation technology, has successfully completed its rights offering with approximately 2x oversubscription. The company raised $10.0 million in gross proceeds through the offering of 10,000,000 units at $1.00 per unit.
Each unit consists of one ordinary share and one warrant, with an alternative option for a pre-funded warrant and warrant combination. The subscription rights were distributed to shareholders of record as of July 9, 2025, with holders receiving one right for every ordinary share owned. A total of 4,627,771 units are expected to be issued through the over-subscription privilege, with delivery expected around July 30, 2025.
IceCure Medical (NASDAQ:ICCM) showcased impressive clinical data for its ProSense® cryoablation technology at the Japanese Breast Cancer Society Conference. Professor Eisuke Fukuma presented data from over 600 breast cancer patients treated between 2006-2023, demonstrating a remarkable 99.02% recurrence-free rate for up to 17 years.
An independent study by Professor Hisanori Kawamoto, which won the Best of Breast Cancer Award, reported 0% local recurrence after 5 years of ProSense® treatment. The company, working with Terumo Corporation, anticipates submitting a regulatory application to Japan's PMDA for breast cancer indication by the end of 2025.
IceCure Medical (Nasdaq: ICCM), a developer of cryoablation technology for tumor treatment, has announced the upcoming expiration of its rights offering subscription period on July 28, 2025, at 5:00 PM ET. The company is offering up to 10,000,000 units at $1.00 per unit.
Shareholders of record as of July 9, 2025, received one subscription right for every ordinary share owned, with each right allowing the purchase of 0.1703 units. Each unit consists of one ordinary share and one warrant, or alternatively, one pre-funded warrant and one warrant. Maxim Group LLC is serving as the dealer-manager, while Broadridge Corporate Issuer Solutions, LLC acts as both the Subscription and Information Agent.
FAQ
What is the current stock price of Icecure Medical Ltd. (ICCM)?
What is the market cap of Icecure Medical Ltd. (ICCM)?
